| Summary: | NICE issued an updated guideline (Clinical Guideline 66) for the management of all aspects of type 2 diabetes in May 2008. However new drug developments means that this guideline itself already requires an update. This technology assessment report aims to provide information to support the Short Guideline Development Group (GDG) which will produce a "new drugs update" to the 2008 guideline. The four classes of drugs which the GDG have been asked to consider are: the glucagon-like peptide 1 analogue, exenatide, in its currently available form, given by injection twice daily (the second drug in that class, liraglutide, was not licensed in time to be included in the guideline update, and nor was the long-acting form of exenatide); the dipeptidyl peptidase 4 inhibitors, sitagliptin and vildagliptin; the long-acting insulin analogues, glargine and detemir (glargine had been the subject of a previous technology appraisal (TA 43) but it was felt that this needed updated and detemir had not previously been appraised by NICE); the thiazolidinediones (hereafter referred to as the glitazones), more from the safety aspects than for glycaemic control
|
|---|